INCY vs. MEDP, CRL, EXEL, NRC, ICLR, IQV, PODD, TECH, THC, and VTRS
Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Medpace (MEDP), Charles River Laboratories International (CRL), Exelixis (EXEL), National Research (NRC), ICON Public (ICLR), IQVIA (IQV), Insulet (PODD), Bio-Techne (TECH), Tenet Healthcare (THC), and Viatris (VTRS).
Incyte (NASDAQ:INCY) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Incyte has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
97.0% of Incyte shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 17.5% of Incyte shares are owned by company insiders. Comparatively, 20.3% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Incyte has a net margin of 19.78% compared to Medpace's net margin of 15.92%. Medpace's return on equity of 59.74% beat Incyte's return on equity.
Incyte currently has a consensus price target of $73.69, indicating a potential upside of 29.82%. Medpace has a consensus price target of $441.67, indicating a potential upside of 11.85%. Given Incyte's higher probable upside, equities analysts clearly believe Incyte is more favorable than Medpace.
Incyte received 872 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 73.58% of users gave Incyte an outperform vote while only 64.07% of users gave Medpace an outperform vote.
In the previous week, Medpace had 4 more articles in the media than Incyte. MarketBeat recorded 19 mentions for Medpace and 15 mentions for Incyte. Medpace's average media sentiment score of 1.08 beat Incyte's score of 0.55 indicating that Medpace is being referred to more favorably in the news media.
Incyte has higher revenue and earnings than Medpace. Incyte is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Summary
Medpace beats Incyte on 10 of the 18 factors compared between the two stocks.
Get Incyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
